Evaluating the Benefits of Lenvatinib and Paclitaxel in Recurrent Gynecologic Cancers

The fast track designation for AVB-001 granted by the FDA recognizes its potential as a treatment option for patients with relapsed/refractory ovarian cancer.

In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.

The observed benefits of ciltacabtagene autoleucel in patients with multiple myeloma and poor prognostic features are consistent with the overall the population of CARTITUDE-4.

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

In the phase 3 CARTITUDE-4 trial, ciltacabtagene autoleucel was shown to be effective when used in patients with multiple myeloma exhibiting poor prognostic features.

IberVd showed high efficacy with deep, ongoing responses among older patients with transplant-ineligible, newly diagnosed multiple myeloma.